According to a press release from the American Academy of Neurology, patients with chronic migraine who began GLP-1 drugs for conditions such as diabetes or weight loss were less likely to require new preventive migraine medication.
They were compared with patients who started topiramate, which is often used to treat migraine.
In the group taking GLP-1 medication, prescriptions for drugs such as valproate, calcitonin gene-related peptide (CGRP) monoclonal antibodies, tricyclic antidepressants, and gepants were issued less frequently. There was no difference in the use of beta blockers.
The researchers note that the difference was consistent across several types of preventive treatment.
Also read: Girls aged 13 to 15 in Europe have the highest tobacco use in the world
Fewer hospital visits
The study is based on health data from approximately 22,000 people with chronic migraine.
The condition is defined as having headaches on at least 15 days per month for three months, with at least eight days involving typical migraine symptoms.
Participants were followed for one year after starting treatment.
Among those receiving GLP-1 medication, 23.7 percent visited the emergency department during the period. In the topiramate group, the figure was 26.4 percent.
Also read: Can daily peanut butter improve strength in older adults? New study provides answers
In addition, the GLP-1 group had fewer hospital admissions, fewer nerve blocks, and fewer prescriptions for triptans, which are used to treat acute migraine attacks.
Requires further research
The study is observational, meaning it cannot establish whether the medication directly caused the differences.
Other factors, such as weight loss or changes in disease severity, may have played a role.
The results are scheduled to be presented at the American Academy of Neurology’s annual meeting in April 2026. However, the researchers emphasize that further studies are needed.
Also read: These bodily symptoms may be linked to high blood pressure
Sources: News Medical, and American Academy of Neurology.
Also read: How to deal with stubborn white spots on the skin
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.